LGM
Logos Global Management Portfolio holdings
AUM
$749M
This Quarter Return
+46.13%
1 Year Return
+18.94%
3 Year Return
+431.72%
5 Year Return
+481.1%
10 Year Return
–
AUM
$899M
AUM Growth
+$899M
(+28%)
Cap. Flow
+$9.42M
Cap. Flow
% of AUM
1.05%
Top 10 Holdings %
Top 10 Hldgs %
62.68%
Holding
71
New
17
Increased
10
Reduced
14
Closed
22
Top Buys
| 1 |
argenx
ARGX
|
$55.2M |
| 2 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$35.3M |
| 3 |
Cytokinetics
CYTK
|
$31.3M |
| 4 |
AMAM
Ambrx Biopharma, Inc. Common Stock
AMAM
|
$28.3M |
| 5 |
Structure Therapeutics
GPCR
|
$23.2M |
Top Sells
| 1 |
ICVX
Icosavax, Inc. Common Stock
ICVX
|
$38.9M |
| 2 |
Sarepta Therapeutics
SRPT
|
$24.2M |
| 3 |
Rocket Pharmaceuticals
RCKT
|
$21M |
| 4 |
Neurocrine Biosciences
NBIX
|
$16.9M |
| 5 |
Immunovant
IMVT
|
$16.9M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Cytokinetics
CYTK
$4.23B
| $136M | 12.66% | 1,625,000 +375,000 | +30% | +$31.3M |
|
2
IDEAYA Biosciences
IDYA
$2.15B
| $64M | 5.98% | 1,800,000 -450,000 | -20% | -$16M |
|
3
Apellis Pharmaceuticals
APLS
$3.48B
| $56.9M | 5.31% | 950,000 +200,000 | +27% | +$12M |
|
|
4
argenx
ARGX
$43.6B
| $55.2M | 5.15% | +145,000 | New | +$55.2M |
|
5
Olema Pharmaceuticals
OLMA
$375M
| $54.4M | 5.08% | 4,383,875 +640,000 | +17% | +$7.94M |
|
|
6
Immunovant
IMVT
$2.56B
| $50.6M | 4.72% | 1,200,000 -400,000 | -25% | -$16.9M |
|
|
7
Structure Therapeutics
GPCR
$1.11B
| $43.6M | 4.07% | 1,070,058 +570,058 | +114% | +$23.2M |
|
|
8
Rocket Pharmaceuticals
RCKT
$354M
| $38.2M | 3.57% | 1,275,000 -700,000 | -35% | -$21M |
|
|
RYZB
9
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $35.3M | 3.3% | +568,173 | New | +$35.3M |
|
|
AMAM
10
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| $29.9M | 2.79% | 2,100,000 +1,985,000 | +1,726% | +$28.3M |
|
|
KRTX
11
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $28.5M | 2.66% | 90,000 -25,000 | -22% | -$7.91M |
|
12
Immunocore
IMCR
$1.62B
| $27.3M | 2.55% | 400,000 -50,000 | -11% | -$3.42M |
|
13
Dyne Therapeutics
DYN
$1.92B
| $25M | 2.33% | 1,880,000 -300,000 | -14% | -$3.99M |
|
14
Annexon
ANNX
$226M
| $22.5M | 2.1% | 4,950,000 -350,000 | -7% | -$1.59M |
|
15
Akero Therapeutics
AKRO
$3.74B
| $18.7M | 1.74% | 800,000 +200,000 | +33% | +$4.67M |
|
16
Ocular Therapeutix
OCUL
$2.12B
| $17.8M | 1.67% | +4,000,000 | New | +$17.8M |
|
|
MOR
17
DELISTED
MorphoSys AG American Depositary Shares
MOR
| $14.6M | 1.36% | 1,475,000 +525,000 | +55% | +$5.2M |
|
18
Design Therapeutics
DSGN
$315M
| $13.3M | 1.24% | 5,032,501 | – | – |
|
19
Viridian Therapeutics
VRDN
$1.5B
| $13.1M | 1.22% | 600,000 -450,000 | -43% | -$9.8M |
|
20
Edgewise Therapeutics
EWTX
$1.51B
| $10.4M | 0.97% | +950,000 | New | +$10.4M |
|
21
Revolution Medicines
RVMD
$7.1B
| $10M | 0.94% | 350,000 +100,000 | +40% | +$2.87M |
|
|
SLRN
22
DELISTED
ACELYRIN
SLRN
| $9.33M | 0.87% | +1,250,000 | New | +$9.33M |
|
23
MoonLake Immunotherapeutics
MLTX
$3.54B
| $9.06M | 0.85% | +150,000 | New | +$9.06M |
|
|
ATYR
24
aTyr Pharma
ATYR
$527M
| $8.25M | 0.77% | +5,850,000 | New | +$8.25M |
|
25
Fulcrum Therapeutics
FULC
$351M
| $8.1M | 0.76% | +1,200,000 | New | +$8.1M |
|